Good evening and welcome to Markets Desk.
Gap Incorporated is taking the biggest hit of the session, with shares collapsing seventeen percent after the retailer missed on both earnings and revenue in the first quarter. Old Navy was the primary drag, and management followed the disappointing print by cutting the full-year sales outlook — a double blow that the market did not forgive.
Shifting to biotech, Oculis is in freefall after its Phase Three DIAMOND-one and DIAMOND-two trials of OCS-zero-one eye drops failed to meet primary and secondary endpoints in diabetic macular edema patients. The key measure — best corrected visual acuity — showed no meaningful improvement, and without that clinical proof of concept, the investment thesis collapses almost entirely.
On a brighter note for tech, Nvidia continues to command attention as the largest component of the S and P five hundred, raising serious questions about concentration risk in the index. Its dominance in AI chip infrastructure means its weight in passive portfolios is no longer trivial — when Nvidia moves, the whole market feels it.
That's the tape. Markets Desk, signing off the floor.
